Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steger

Showing results (231-240 of 320) with videos related to

Pageof 32
Sort By:
The Breast Journal|January 29, 2013
Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancerAnna S Berghoff, Zsuzsanna Bago-Horvath, Peter Dubsky, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 1998
Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study GroupR Jakesz, H Samonigg, M Gnant, et al.
Breast Cancer Research and Treatment|January 22, 2010
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I studyUrsula Wiedermann, C Wiltschke, J Jasinska, et al.
BMC Cancer|May 8, 2020
Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive TrialV Bjelic-Radisic, F Fitzal, M Knauer, et al.
BMC Cancer|March 17, 2006
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational studyRupert Bartsch, Catharina Wenzel, Dagmar Hussian, et al.
ESMO Open|May 29, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trialP Filis, X Liu, A Matikas, et al.
European Journal of Clinical Investigation|November 28, 1997
Cisplatin-induced renal effects and thromboxane A2 receptor blockadeG T Dorner, H Pehamberger, G Kornek, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Journal of Neuro-Oncology|June 9, 2007
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancerRupert Bartsch, Andrea Rottenfusser, Catharina Wenzel, et al.
Onkologie|May 18, 2011
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern EuropeRichard Greil, Simona Borštnar, Katarína Petráková, et al.
Pageof 32

Showing results (231-240 of 320) with videos related to

Sort By:
Pageof 32
The Breast Journal|January 29, 2013
Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancerAnna S Berghoff, Zsuzsanna Bago-Horvath, Peter Dubsky, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 1998
Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study GroupR Jakesz, H Samonigg, M Gnant, et al.
Breast Cancer Research and Treatment|January 22, 2010
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I studyUrsula Wiedermann, C Wiltschke, J Jasinska, et al.
BMC Cancer|May 8, 2020
Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive TrialV Bjelic-Radisic, F Fitzal, M Knauer, et al.
BMC Cancer|March 17, 2006
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational studyRupert Bartsch, Catharina Wenzel, Dagmar Hussian, et al.
ESMO Open|May 29, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trialP Filis, X Liu, A Matikas, et al.
European Journal of Clinical Investigation|November 28, 1997
Cisplatin-induced renal effects and thromboxane A2 receptor blockadeG T Dorner, H Pehamberger, G Kornek, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Journal of Neuro-Oncology|June 9, 2007
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancerRupert Bartsch, Andrea Rottenfusser, Catharina Wenzel, et al.
Onkologie|May 18, 2011
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern EuropeRichard Greil, Simona Borštnar, Katarína Petráková, et al.
Pageof 32